



- (51) **International Patent Classification:**
C07D 263/52 (2006.01) *C07D 498/00* (2006.01)
- (21) **International Application Number:**
PCT/US2012/042622
- (22) **International Filing Date:**
15 June 2012 (15.06.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/498,110 17 June 2011 (17.06.2011) US
- (71) **Applicant (for all designated States except US):** **GLAXO-SMITHKLINE LLC** [US/US]; One Franklin Plaza, 200 North 16th Street, Philadelphia, PA 19102 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **BROOKS, Carl** [GB/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **CHEUNG, Mui** [US/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **EIDAM, Hilary, Schenck** [US/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **GOODMAN, Krista, B.** [US/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **HAMMOND, Marlys** [US/US]; 4359 W. Ponds Circle, Littleton, CO 80123 (US). **HILFIKER, Mark, A.** [US/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **HOANG, Tram, H.** [US/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **PATTERSON, Jaclyn, R.** [US/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **STOY, Patrick** [US/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US). **YE, Guosen** [US/US]; 709 Swedeland Road, King of Prussia, PA 19406 (US).

- (74) **Agents:** **HALL, Linda, E.** et al.; Glaxosmithkline, Global Patents, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) **Title:** TRPV4 ANTAGONISTS

(57) **Abstract:** The present invention relates to spirocarbamate compounds of Formula (I) in which R₁, (R₂)Y, R₃, R₄, X and A have the meanings given in the specification. The invention further provides pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and relates to their use of these compounds as TRPV4 antagonists in treating or preventing conditions associated with TRPV4 imbalance.

